DJIA 17,025.40 -5.74 -0.03%
NASDAQ 4,518.43 -0.47 -0.01%
S&P 500 1,986.68 2.55 0.13%
market minute promo

Geron Corp (NASDAQ: GERN)

2.34 -0.04 (-1.68%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GERN $2.34 -1.68%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.35
Previous Close $2.38
Daily Range $2.34 - $2.37
52-Week Range $1.39 - $7.79
Market Cap $367.1M
P/E Ratio -9.52
Dividend (Yield) $0.00 (0.0%)
Volume 199,816
Average Daily Volume 2,032,578
Current FY EPS -$0.23





Geron Corp (GERN) Description

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. Website:

News & Commentary Rss Feed

3 Longtime Losers About to See Green?

These 3 biotechs have lost tons of money every year so far in the 21st century. But could profits be on the horizon?

Why You Shouldn't Bet Against Geron Corporation (GERN) Stock - Tale of the Tape

Geron: Best Buy In The Market

Geron's (GERN) CEO John Scarlett on Q2 2014 Results - Earnings Call Transcript

Geron's (GERN) CEO John Scarlet on Q2 2014 Results - Earnings Call Transcript

Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market

Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation

Better Buy: Dynavax Technologies Corp. vs. Geron Corp.

Dynavax Technologies Corp. and Geron Corp. have pending catalysts that could cause their shares to double from current levels. Here's a Foolish look at which company offers the better risk-to-reward profile.

Geron Corp. (GERN) Jumps: Stock Moves 8.1% Higher - Tale of the Tape

Geron (GERN) Enters Overbought Territory - Tale of the Tape

See More GERN News...

GERN's Top Competitors

GERN $2.34 (-1.68%)
Current stock: GERN
AMGN $137.13 (-0.61%)
Current stock: AMGN
GILD $102.57 (1.56%)
Current stock: GILD
BIIB $323.10 (0.93%)
Current stock: BIIB